Retroperitoneal Fibrosis Clinical Trial
Official title:
Aortitis and Retroperitoneal Fibrosis: Evaluation of Diagnostic Criteria
Inflammatory aortitis probably represents a heterogeneous group, and the clinical experience
accumulated over the last ten years, shared by the experts of the subject, is that the
initial clinical, biological or radiological characteristics should make it possible to
differentiate them and dismember the Nosological field.
This will be an essential first step before studying prognosis, risk factors, and
therapeutic options.
The search for diagnostic criteria on a large series, similar to the study of classification
of vascularites of the ACR in 1990, should make it possible to homogenize the diagnoses for
the different teams working on the subject, and to begin work Collaborations, which alone
can improve patient care in the future.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT00440349 -
Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis
|
Phase 2 | |
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Recruiting |
NCT04047576 -
Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis
|
Phase 2/Phase 3 | |
| Completed |
NCT02705638 -
Treatment of IgG4-Related Disease With Revlimid and Rituximab
|
Phase 1 | |
| Completed |
NCT01584388 -
Rituximab in IgG4-related Disease: A Phase 1-2 Trial
|
Phase 1/Phase 2 |